Open AccessEstrogen Plus Progestin Hormone Therapy and Ovarian Cancer
Author(s) -
Alice W. Lee,
Anna H. Wu,
Ashley Wiensch,
Bhramar Mukherjee,
Kathryn L. Terry,
Holly R. Harris,
Michael E. Carney,
Allan Jensen,
Daniel W. Cramer,
Andrew Berchuck,
Jennifer A. Doherty,
Francesmary Modugno,
Marc T. Goodman,
Aliya Alimujiang,
Mary Anne Rossing,
Kara L. CushingHaugen,
Elisa V. Bandera,
Pamela J. Thompson,
Susanne Krüger Kjær,
Estrid Høgdall,
Penelope M. Webb,
David G. Huntsman,
K.B. Moysich,
Galina Lurie,
Roberta B. Ness,
Daniel O. Stram,
Lynda D. Roman,
Malcolm C. Pike,
Celeste Leigh Pearce
Publication year - 2020
Publication title -
epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.901
H-Index - 173
eISSN - 1531-5487
pISSN - 1044-3983
DOI - 10.1097/ede.0000000000001175
Subject(s) - medicine , progestin , estrogen , ovarian cancer , endometrial cancer , oncology , serous fluid , gynecology , cancer , menopause
Menopausal estrogen-alone therapy is a risk factor for endometrial and ovarian cancers. When a progestin is included with the estrogen daily (continuous estrogen-progestin combined therapy), there is no increased risk of endometrial cancer. However, the effect of continuous estrogen-progestin combined therapy on risk of ovarian cancer is less clear.